Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.
Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share. Although rejecting GSK’s initial bid, HGS kept the door open for other suitors, including again GSK.
HGS has authorized its board of directors to explore strategic alternatives for the company, including a potential sale. HGS has invited GSK to participate in this process and has requested additional information regarding investigational products in GSK’s clinical pipeline to which HGS has substantial financial rights, including darapladib, in Phase III development for treating cardiovascular disease, and albiglutide, in Phase III development for treating Type 2 diabetes.
HGS posted a net loss of $381.1 million in 2011 on revenues of $131 million and also posted a loss in 2010 of $233 million. Last year, HGS received FDA approval for Benlysta (belimumab), a drug to treat lupus. The drug was approved by FDA in March 2011 and posted 2011 revenues of $52.3 million. In 2006, HGS and GSK entered into a codevelopment and commercialization agreement under which HGS conducted the Benlysta Phase II trials, with assistance from GSK. The companies share equally in Phase III/IV development costs, sales, and marketing expenses, and profits of any product commercialized under the agreement.
Although HGS rejected GSK’s $13.00-per-share bid, the companies’ mutual interest in Benlysta and in the late-stage candidates darapladib and albiglutide make them possible suitors. Some analysts say it is unlikely that another company would be interested in HGS given its stake in the GSK-shared drugs.
Analysts say the deal would be favorable to GSK for it would secure full ownership of Benlysta and the late-stage candidates darapladib and albiglutide. When approved last year, Benlysta became the first new drug to treat lupus in 50 years, and although it has gotten off to a slow start in terms of sales, some analysts are bullish on its prospects as well as the other HGS/GSK late-stage candidates.
So time will tell if a marriage of GSK and HGS will be realized.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.